Tevogen (TVGN) Non-Current Assets (2021 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Non-Current Assets came in at $2.8 million in Q1 2026, up 179.29% YoY from $995371.0 in Q1 2025, and down 2.22% on a QoQ basis from $2.8 million in Q4 2025.
Tevogen (TVGN) Non-Current Assets (2021 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 6 years of Non-Current Assets data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Non-Current Assets rose 179.29% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (up 174.18% YoY) and the FY2025 annual result came in at $2.8 million, up 158.29% from the prior year.
- Non-Current Assets retreated to $2.8 million in Q1 2026, from $2.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $356.9 million in Q4 2022 to a low of $761755.0 in Q3 2024.
- A 5-year average of $88.9 million and a median of $2.8 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets sank 98.94% — and 2025, when it soared 211.38%.
- Tracing TVGN's Non-Current Assets over 5 years: stood at $356.9 million in 2022, then slumped by 98.94% to $3.8 million in 2023, then sank by 70.9% to $1.1 million in 2024, then surged by 158.29% to $2.8 million in 2025, then slipped by 2.22% to $2.8 million in 2026.
- The last three Non-Current Assets figures came in at $2.8 million (Q1 2026), $2.8 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.78 Mn |
| Dec 31, 2025 | 2.84 Mn |
| Sep 30, 2025 | 2.37 Mn |
| Jun 30, 2025 | 2.21 Mn |
| Mar 31, 2025 | 995,371.00 |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 761,755.00 |
| Jun 30, 2024 | 863,496.00 |
| Mar 31, 2024 | 963,486.00 |
| Dec 31, 2023 | 3.78 Mn |
| Sep 30, 2023 | 26.01 Mn |
| Jun 30, 2023 | 25.68 Mn |
| Mar 31, 2023 | 25.37 Mn |
| Dec 31, 2022 | 356.86 Mn |
| Sep 30, 2022 | 354.12 Mn |
| Jun 30, 2022 | 352.38 Mn |
| Mar 31, 2022 | 352.10 Mn |
| Dec 31, 2021 | 352.06 Mn |